Skip to Content
NIH - National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Center for Cancer Research
NCI Experimental Therapeutics Program (NExT)
Contact NExT
Show menu
Search this site
Last Updated: 12/02/15

Phase 0 – I NExT Projects

Applicant Institute Project
Allen, Andrew Clovis Oncology, Inc. Combination therapies to overcome CO-1686 resistance in mutant EGFR NSCLC
Barry, Simon AstraZeneca AB AZD8186 targeting PI3Kbeta and delta for solid and hematological tumours
Davis, Thomas Celldex Therapeutics, Inc. Continued Development of the Varlilumab (CDX-1127)
Dorr, Andrew BioMarin Pharmaceutical Inc. Patient Selection Assay Strategies to Predict Patients That Respond to PARP
Gromeier, Matthias Duke University Acquisition of Bulk Substance (cGMP) PVS-RIPO for Extended Clinical Studies
Healy, Denis Kyowa Hakko Kirin Pharma, Inc. Mogamulizumab (a recombinant, humanized monoclonal antibody)
Hussein, Mohamad Celgene Corporation Pomalidomide in Rare Diseases with Unmet Medical Needs
Miller, Jeffrey University of Minnesota - Twin Cities rhIL-15 to Exploit NK Cells in Cancer Therapy
Pluda, James Merck Sharp & Dohme, Corp. Merck & Co., Inc. Agent MK-3475, an Anti-PD1 Monoclonal Antibody (mAb)
Reynolds, Patrick Texas Tech University
Health Sciences Center
NSC71503 (Safingol)
Sikorski, Robert MedImmune/AstraZeneca MedImmune MEDI-570
Smith, Malcolm National Institute of Cancer, NIH Ch14.18 Production
Suto, Mark Southern Research Institute Preclinical Development of T-dCyd: A New Epigenetic Agent
Wadsworth, Catherine AstraZeneca AZD9291 3rd Generation EGFR TKI NExT Partnership with NCI Application
Wagner, Anthony Amgen Incorporated Ganitumab (AMG 479) CRADA
Wagner, Anthony Amgen Incorporated AMG 337 NExT Application
Wagner, Anthony Amgen Incorporated AMG 232 NExT Application